IP Verse

Fibrogen, Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Fibrogen, Inc.

Patent Number:
EP3357911
Title:
Prolyl Hydroxylase Inhibitors And Methods Of Use
Applicant:
AKEBIA THERAPEUTICS INC.
Opposition Date:
Feb 13, 2023

Latest patents of Fibrogen, Inc. opposed by its competitors

Patent:
EP2298301
Grant Date:
Nov 16, 2022
Title:
Medicaments For Increasing Endogenous Erythropoietin (Epo)
Oppositions:
1
Patent:
EP3470397
Grant Date:
Dec 29, 2021
Title:
Crystalline Forms Of A Prolyl Hydroxylase Inhibitor
Oppositions:
3
Patent:
EP3003284
Grant Date:
Feb 12, 2020
Title:
Pharmaceutical Formulations Of A Hif Hydroxylase Inhibitor
Oppositions:
2
Patent:
EP2324834
Grant Date:
May 8, 2019
Title:
Methods Of Increasing Endogenous Erythropoietin (Epo)
Oppositions:
1
Patent:
EP2872488
Grant Date:
Aug 22, 2018
Title:
Crystalline Forms Of A Prolyl Hydroxylase Inhibitor
Oppositions:
3
Patent:
EP2289531
Grant Date:
Jul 4, 2018
Title:
Medicaments For Increasing Endogenous Erythropoietine (Epo)
Oppositions:
2
Patent:
EP2322153
Grant Date:
Oct 8, 2014
Title:
Use Of Hif Alpha Stabilizers For Enhancing Erythropoiesis
Oppositions:
4

Competitors of Fibrogen, Inc.

AKEBIA THERAPEUTICS, INC.

SANDOZ AG

GLAXOSMITHKLINE UK LIMITED

Want to track Fibrogen, Inc.?

Feel free to send us a message here and we will get back to you